JP2010534464A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534464A5
JP2010534464A5 JP2010517326A JP2010517326A JP2010534464A5 JP 2010534464 A5 JP2010534464 A5 JP 2010534464A5 JP 2010517326 A JP2010517326 A JP 2010517326A JP 2010517326 A JP2010517326 A JP 2010517326A JP 2010534464 A5 JP2010534464 A5 JP 2010534464A5
Authority
JP
Japan
Prior art keywords
peptide
cell
variant
antigen
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010517326A
Other languages
English (en)
Japanese (ja)
Other versions
JP6008461B2 (ja
JP2010534464A (ja
Filing date
Publication date
Priority claimed from EP08005889.4A external-priority patent/EP2105501B1/en
Application filed filed Critical
Priority claimed from PCT/EP2008/006154 external-priority patent/WO2009015843A1/en
Publication of JP2010534464A publication Critical patent/JP2010534464A/ja
Publication of JP2010534464A5 publication Critical patent/JP2010534464A5/ja
Application granted granted Critical
Publication of JP6008461B2 publication Critical patent/JP6008461B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010517326A 2007-07-27 2008-07-25 神経細胞性脳腫瘍に対する新規免疫療法 Expired - Fee Related JP6008461B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07014797.0 2007-07-27
EP07014797 2007-07-27
US95316107P 2007-07-31 2007-07-31
US60/953,161 2007-07-31
EP08005889.4A EP2105501B1 (en) 2008-03-27 2008-03-27 Novel immunotherapy against neuronal and brain tumors
EP08005889.4 2008-03-27
PCT/EP2008/006154 WO2009015843A1 (en) 2007-07-27 2008-07-25 Novel immunotherapy against neuronal and brain tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013112532A Division JP5738348B2 (ja) 2007-07-27 2013-05-29 神経細胞性脳腫瘍に対する新規免疫療法

Publications (3)

Publication Number Publication Date
JP2010534464A JP2010534464A (ja) 2010-11-11
JP2010534464A5 true JP2010534464A5 (enExample) 2010-12-24
JP6008461B2 JP6008461B2 (ja) 2016-10-19

Family

ID=39720257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010517326A Expired - Fee Related JP6008461B2 (ja) 2007-07-27 2008-07-25 神経細胞性脳腫瘍に対する新規免疫療法
JP2013112532A Expired - Fee Related JP5738348B2 (ja) 2007-07-27 2013-05-29 神経細胞性脳腫瘍に対する新規免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013112532A Expired - Fee Related JP5738348B2 (ja) 2007-07-27 2013-05-29 神経細胞性脳腫瘍に対する新規免疫療法

Country Status (21)

Country Link
US (6) US9175040B2 (enExample)
EP (2) EP2660248B1 (enExample)
JP (2) JP6008461B2 (enExample)
KR (2) KR101317989B1 (enExample)
CN (2) CN103911358B (enExample)
AU (1) AU2008281015B2 (enExample)
BR (1) BRPI0813621A2 (enExample)
CA (2) CA2694808C (enExample)
CY (1) CY1117115T1 (enExample)
DK (2) DK2183361T3 (enExample)
EA (2) EA034800B1 (enExample)
ES (2) ES2546610T3 (enExample)
HR (2) HRP20150820T1 (enExample)
HU (1) HUE027524T2 (enExample)
MX (1) MX2010001086A (enExample)
NZ (2) NZ592261A (enExample)
PL (2) PL2183361T3 (enExample)
PT (2) PT2183361E (enExample)
RS (2) RS54204B1 (enExample)
SI (2) SI2660248T1 (enExample)
WO (1) WO2009015843A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
HRP20150820T1 (xx) * 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapija protiv neuronskih tumora i tumora mozga
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2661622B1 (en) * 2011-01-05 2017-11-08 Wisconsin Alumni Research Foundation Bystander immune suppression as a predictor for response to a vaccine
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20230563A (es) * 2015-07-06 2024-01-22 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI782434B (zh) * 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
AU2017305396A1 (en) * 2016-08-02 2019-02-21 Nant Holdings Ip, Llc Transfection of dendritic cells and methods therefor
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
CA3170412A1 (en) * 2020-02-24 2021-09-02 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
EP4405464A4 (en) * 2021-09-21 2025-12-03 Univ Chicago METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (enExample) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
JPS6081130A (ja) * 1983-10-07 1985-05-09 Fujisawa Pharmaceut Co Ltd 抗ｈｌａ−ａ２抗体およびそれを産生するハイブリド−マ
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5651972A (en) * 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5202666A (en) * 1991-01-18 1993-04-13 Net/Tech International Inc. Method and apparatus for enhancing hygiene
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1996031604A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE19739089A1 (de) * 1997-09-06 1999-03-11 Hella Kg Hueck & Co Scheinwerfer für Fahrzeuge
EP1015616A2 (en) * 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
CA2375145A1 (en) * 1999-06-03 2000-12-14 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
US6455026B1 (en) 2001-03-23 2002-09-24 Agy Therapeutics, Inc. Use of protein tyrosine phosphatase zeta as a biomolecular target in the treatment and visualization of brain tumors
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
JP2003012544A (ja) * 2001-03-27 2003-01-15 Kouji Egawa 癌予防・治療剤
US20050260132A1 (en) * 2001-10-17 2005-11-24 Daniel Chin Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
AU2002365187A1 (en) * 2001-11-07 2003-07-24 Mannkind Corporation Epitope synchronization in antigen presenting cells
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7236577B2 (en) * 2002-11-14 2007-06-26 International Business Machines Corporation Call screening system and method
KR100494979B1 (ko) * 2003-07-14 2005-06-14 주식회사 정우인터내셔날 조직 절편 보호 및 해상력 증진용 액상 커버 슬립, 그제조용 조성물, 그로부터 제조된 커버슬립을 구비한슬라이드 구조체 및 그 제조방법
US7050785B2 (en) * 2003-12-08 2006-05-23 Research In Motion Limited Apparatus and method of explicit indication of call from emergency call centre
AU2005206389A1 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7315736B2 (en) * 2004-09-30 2008-01-01 Jenkins Nevin C Personal emergency communication system
US7231200B2 (en) * 2004-09-30 2007-06-12 Nevin Jenkins Personal emergency communication system
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
HRP20150820T1 (xx) * 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapija protiv neuronskih tumora i tumora mozga
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2015187040A1 (en) * 2014-06-05 2015-12-10 Regan James Anderson Amino sphingoglycolipid analogues

Similar Documents

Publication Publication Date Title
JP2010534464A5 (enExample)
AU2017331949B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
van der Burg et al. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy
JP2017502076A5 (enExample)
JP5166025B2 (ja) エピトープアナログ
JP2010534463A5 (enExample)
JP3819930B2 (ja) Ｗｔ１改変ペプチド
AU2016232659B2 (en) A novel complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer
CA2886631C (en) Pam3cys-like lipopeptide adjuvant compound in a vaccine composition
HRP20150852T1 (hr) Nova imunoterapija protiv tumora mozga
EA201892021A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
EA201891759A1 (ru) Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний
AU2018229741B2 (en) Peptides and methods for the treatment of diabetes
KR19990067653A (ko) 종양 백신 및 그의 제조 방법
AU2015233542B2 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
JP6602377B2 (ja) 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途
JP5546448B2 (ja) ＭＨＣクラスＩＩ分子に提示されるサーバイビン（Ｓｕｒｖｉｖｉｎ）の部分ペプチドとその利用法
JP5267969B2 (ja) 癌ワクチン
Levy et al. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response
CN101041816B (zh) 人工抗原递呈细胞及其制备方法
JP2021045150A5 (enExample)
Ahmadzadeh OR. 93. Tumor Antigen-specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and are Functionally Impaired
Sabbagh et al. OR. 92. Human Glioblastoma Cancer Stem Cells Promote Intra-tumoral Immune Regulatory Functions
Feng et al. Inducement of antitumor-immunity by DC activated by Hsp70-H22 tumor antigen peptide
Eggermont et al. Antigen-specific T cell activation using filamentous synthetic Dendritic Cells